GlassScriptPhysician profile
Mwelwa Chizinga
NPI 1962899476
$1,681.49
in general payments reported to CMS, 2019-2025
22 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.62 · 2022: $309 · 2023: $615 · 2024: $403 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.57 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343.22 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $313.75 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.32 | 2023-2024 | Ofev |
| Stryker Corporation | $133.32 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $131.82 | 2024 | Impella |
| Jazz Pharmaceuticals INC. | $79.58 | 2023 | Xywav |
| Insmed, INC. | $70.92 | 2022-2023 | Arikayce |
| Grifols USA, LLC | $68.02 | 2023-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $66.48 | 2022-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $50.74 | 2023-2024 | Glassia |
| Amgen INC. | $40.63 | 2022-2024 | Tezspire |
| Genzyme Corporation | $33.97 | 2024 | |
| Philips North America LLC | $31.63 | 2023 | |
| Novartis Pharmaceuticals Corporation | $28.66 | 2025 | |
| Pfizer INC. | $24.77 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $20.49 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $19.88 | 2023 | Nuzyra |
| Electromed, INC. | $19.35 | 2025 | Smartvest |
| Pulmonx Corporation | $17.39 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| E.R. Squibb & Sons, L.L.C. | $14.12 | 2022 | |
| Inogen, INC. | $13.94 | 2023 | Inogen At Home Stationary Concentrator |
| Janssen Pharmaceuticals, INC | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mwelwa Chizinga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.